pharmaphorum

AUGUST 10, 2021

Europe market has proved so hostile to gene therapies when it comes to pricing and reimbursement for gene therapies that bluebird bio has decided to quit the market altogether, according to Andrew Obenshain, president of its severe genetic diseases unit. market and will wind down in Europe.

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

BioTech 365

NOVEMBER 23, 2020

Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com Companion Diagnostics Markets, 2025 – Immunohistochemistry, Polymerase Chain Reaction, In-situ Hybridization, Real-time PCR, Gene Sequencing – ResearchAndMarkets.com (..)

Gene Sequencing 40

Gene Sequencing Gene Marketing 40

pharmaphorum

JUNE 23, 2022

billion in potential milestones if the project advances through development and onto the market. Systemic administration of gene-editing drugs would avoid that process with an “off-the-shelf” option for a one-shot, potentially curative treatment for diseases associated with genetic mutations.

Gene Editing 97

Gene Editing In-Vivo Gene Sequencing Gene 97

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genomics 52

pharmaphorum

OCTOBER 1, 2021

The post Oxford Nanopore makes stellar debut on UK stock market appeared first on. It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.

Marketing 52

Marketing Genomics Genome Business Development 52

pharmaphorum

AUGUST 21, 2020

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches like gene sequencing.

DNA 59

DNA Gene Sequencing Genetics FDA Approval 59

pharmaphorum

SEPTEMBER 14, 2022

SparingVision’s lead candidates are both targeting inherited retinal diseases (IRDs), a group which already has a gene therapy on the market in Novartis’ Luxturna (voretigene neparvovec), which was approved by the FDA in 2017 for biallelic RPE65 mutation-associated retinal dystrophy, a group which includes a small group of RP patients.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Editing 52